<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies have demonstrated that RNAi is a promising approach for treating <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> disorders </plain></SENT>
<SENT sid="1" pm="."><plain>However, discrimination between <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant transcripts is essential, to preserve <z:mp ids='MP_0002169'>wild-type</z:mp> expression and function </plain></SENT>
<SENT sid="2" pm="."><plain>A single nucleotide polymorphism (SNP) is present in more than 70% of patients with <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated whether this SNP could be used to inactivate mutant ataxin-3 selectively </plain></SENT>
<SENT sid="4" pm="."><plain>Lentiviral-mediated silencing of mutant human ataxin-3 was demonstrated in vitro and in a rat model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>The allele-specific silencing of ataxin-3 significantly decreased the severity of the neuropathological abnormalities associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>These data demonstrate that RNAi has potential for use in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> treatment and constitute the first proof-of-principle for allele-specific silencing in the central <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
</text></document>